These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2047 related items for PubMed ID: 18230960

  • 1. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [Abstract] [Full Text] [Related]

  • 2. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Cardiovasc Diabetol; 2006 Sep 26; 5():20. PubMed ID: 17002798
    [Abstract] [Full Text] [Related]

  • 3. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2012 Oct 11; 11():125. PubMed ID: 23057687
    [Abstract] [Full Text] [Related]

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 11; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Oct 11; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 6. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2012 Nov 14; 11():140. PubMed ID: 23150952
    [Abstract] [Full Text] [Related]

  • 7. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2010 Jun 15; 9():24. PubMed ID: 20550659
    [Abstract] [Full Text] [Related]

  • 8. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ.
    Atheroscler Suppl; 2011 Nov 15; 12(3):277-84. PubMed ID: 22152282
    [Abstract] [Full Text] [Related]

  • 9. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M, Roberts A, Davies S, Rees A.
    Drugs; 2004 Nov 15; 64(11):1181-96. PubMed ID: 15161326
    [Abstract] [Full Text] [Related]

  • 10. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR, Knight M.
    Clin Ther; 2015 Oct 01; 37(10):2153-79. PubMed ID: 26412799
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
    Schulz I.
    Arq Bras Endocrinol Metabol; 2006 Apr 01; 50(2):344-59. PubMed ID: 16767301
    [Abstract] [Full Text] [Related]

  • 12. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
    AIM-HIGH InvestigatorsAxio Research, LLC, Seattle, WA, USA. ruthm@axioresearch.com.
    Am Heart J; 2011 Mar 01; 161(3):538-43. PubMed ID: 21392609
    [Abstract] [Full Text] [Related]

  • 13. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
    Ducobu J, Scheen AJ, Legat P, De Backer G, Van Gaal L, Velkeniers B, Kartounian J, Maes M, Hermans M.
    Rev Med Liege; 2009 Oct 01; 64(10):512-8. PubMed ID: 19911665
    [Abstract] [Full Text] [Related]

  • 14. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD.
    Curr Diab Rep; 2019 Nov 21; 19(12):146. PubMed ID: 31754844
    [Abstract] [Full Text] [Related]

  • 15. Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
    Nakajima K.
    Curr Clin Pharmacol; 2010 May 21; 5(2):133-9. PubMed ID: 20156152
    [Abstract] [Full Text] [Related]

  • 16. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z.
    Nutr Metab Cardiovasc Dis; 2013 Sep 21; 23(9):799-807. PubMed ID: 23932901
    [Abstract] [Full Text] [Related]

  • 17. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.
    Am J Cardiovasc Drugs; 2007 Sep 21; 7(1):39-58. PubMed ID: 17355165
    [Abstract] [Full Text] [Related]

  • 18. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
    AIM-HIGH InvestigatorsAxio Research, LLC, Seattle, WA, USA. ruthm@axioresearch.com.
    Am Heart J; 2011 Mar 21; 161(3):471-477.e2. PubMed ID: 21392600
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy of statins and fibrates in the management of cardiovascular risk.
    Fiévet C, Staels B.
    Curr Opin Lipidol; 2009 Dec 21; 20(6):505-11. PubMed ID: 19829109
    [Abstract] [Full Text] [Related]

  • 20. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
    Sharma M, Ansari MT, Abou-Setta AM, Soares-Weiser K, Ooi TC, Sears M, Yazdi F, Tsertsvadze A, Moher D.
    Ann Intern Med; 2009 Nov 03; 151(9):622-30. PubMed ID: 19884623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 103.